生物制剂治疗类风湿关节炎的最新进展

被引：20

作者：

隗佳 ^{[1
]}

张胜桃 ^{[2
]}

机构：

[1] 华中科技大学同济医学院附属同济医院血液内科

[2] 华中科技大学同济医学院附属同济医院风湿内科

来源：

实用医学杂志 | 2010年 / 26卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R593.22 [类风湿性关节炎];

学科分类号：

100201 [内科学];

摘要：

<正>类风湿关节炎(RA)是一类以关节炎为主要临床表现的慢性炎性疾病,以手、足的小关节受累为主,并可累及全身其他系统。循证医学证实,合理使用缓解病情的抗风湿药(DMARDs)可以缓解RA患者病情,延缓骨破坏。在生物制剂出现以前,传统的抗风湿治疗药

引用

页码：1842 / 1844

页数：3

共 9 条

[1]

Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis [J].

Wakabayashi, Hiroki ;

Sudo, Akihiro ;

Hasegawa, Masahiro ;

Oka, Hiroshi ;

Uchida, Atsumasa ;

Nishioka, Kusuki .

CLINICAL RHEUMATOLOGY, 2010, 29 (06) :671-675

[2]

Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis [J].

Chen, Der-Yuan ;

Chou, Show-Jan ;

Hsieh, Tsu-Yi ;

Chen, Yi-Hsing ;

Chen, Hsin-Hua ;

Hsieh, Chia-Wei ;

Lan, Joung-Liang .

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (04) :310-319

[3]

Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis [J].

Sato, Hiroe ;

Sakai, Takehito ;

Sugaya, Toshiaki ;

Otaki, Yasuhiro ;

Aoki, Kana ;

Ishii, Katsushi ;

Horizono, Hidehiro ;

Otani, Hiroshi ;

Abe, Asami ;

Yamada, Noboru ;

Ishikawa, Hajime ;

Nakazono, Kiyoshi ;

Murasawa, Akira ;

Gejyo, Fumitake .

CLINICAL RHEUMATOLOGY, 2009, 28 (09) :1113-1116

[4]

Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis [J].

Jamal, Shahin ;

Patra, Kaushik ;

Keystone, Edward C. .

CLINICAL RHEUMATOLOGY, 2009, 28 (04) :413-419

[5]

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice&colon; adverse events and other reasons for discontinuation of treatment.[J].T. Levälampi;M. Korpela;K. Vuolteenaho;E. Moilanen.Scandinavian Journal of Rheumatology.2008, 1

[6]

Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice:: adverse events and other reasons leading to discontinuation of the treatment [J].